FDA PMA
FDA Class 3
Approved
🇺🇸 United States
Immunohistochemistry Test, Dna Mismatch Repair (Mmr) Protein Assay
PMA: P210001
·
Decision Aug 17, 2021
Classifications
1
FEI Numbers
1
Registration Numbers
1
Basic Information
- Device Name
- Immunohistochemistry Test, Dna Mismatch Repair (Mmr) Protein Assay
- Trade Name
- VENTANA MMR RxDx Panel
- PMA Number
- P210001
- Device Class
- FDA Class 3
- Product Code
- QNH
- Generic Name
- Immunohistochemistry test, DNA mismatch repair (MMR) Protein assay
- Regulation Number
- 864.1860
- Medical Specialty
- Hematology
- Advisory Committee
- Pathology
- Decision
- Approved
- Decision Code
- APPR
- Decision Date
- August 17, 2021
- Date Received
- January 22, 2021
- Expedited Review
- N
- Docket Number
- 21M-0915
Advisory Committee Statement
Approval for the Ventana MMR RxDx Panel as a CDx for identifying patients with solid tumors with dMMR status who may benefit from treatment with JEMPERLI.
Classifications
This FDA Pre-Market Approval entry is associated with 1 FDA classification via its product code.
| Product Code | Device Name | Device Class | Medical Specialty |
|---|---|---|---|
| QNH | Immunohistochemistry Test, Dna Mismatch Repair (Mmr) Protein Assay | FDA class 3 | Hematology |